eligibility_summary
Inclusion: NDMM, transplant‑eligible, ECOG ≤2, contraception (neg preg test if F), well‑controlled HIV allowed, labs: Hb≥8, Plt≥75, ANC≥1.0, AST/ALT≤2.5xULN, eGFR≥30, bili<1.5xULN. Exclusion: WM/POEMS/AL/CNS MM, neuropathy ≥G2, active/high‑risk cancer, serious CV disease/recent stroke, uncontrolled disease/infection, active HBV/HCV, prior MM therapy/SCT, recent major surgery, study‑drug allergy/contra, recent vax/biologics/strong CYP3A4 inducers, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 trial in transplant-eligible newly diagnosed multiple myeloma tests sequential consolidation with talquetamab then teclistamab after induction with Dara-VRd. Drugs/mechanisms (type): Talquetamab (bispecific T-cell engager, GPRC5D×CD3) redirects T cells to kill GPRC5D+ myeloma cells. Teclistamab (bispecific T-cell engager, BCMA×CD3) redirects T cells to BCMA+ plasma cells. Daratumumab (anti-CD38 monoclonal antibody) induces ADCC/ADCP/CDC and apoptosis. Bortezomib (proteasome inhibitor) blocks 26S proteasome, suppresses NF-kB, triggers apoptosis. Lenalidomide (IMiD) binds cereblon to degrade IKZF1/3, boosts T/NK cytotoxicity, anti-angiogenic. Dexamethasone (corticosteroid) activates glucocorticoid receptor, inducing lymphoid apoptosis. Targets: T cells via CD3, malignant plasma cells via GPRC5D, BCMA, CD38, proteasome/ubiquitin pathway, cereblon–IKZF1/3 axis, NF-kB. Aim: deepen responses/MRD negativity.